Beam Therapeutics (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, reported fourth-quarter and full-year 2025 financial results on February 24, 2026.
Alpharetta, Georgia-based Avanos Medical (NYSE:AVNS), a medical technology company focused on pain management and chronic care solutions, reported fourth-quarter and full-year 2025 financial results on February 24, 2026.
Henry Schein (NASDAQ:HSIC) reported a 7.7% increase in fourth-quarter net sales, reaching $3.4 billion as the company benefited from a rebound in high-margin dental equipment and specialty product demand.
Fresenius Medical Care (NYSE:FMS) reported fourth-quarter financial results that exceeded Wall Street expectations, signaling a robust conclusion to its fiscal 2025.
Allurion Technologies (NYSE:ALUR) received U.S. Food and Drug Administration (FDA) premarket approval (PMA) for its Allurion Gastric Balloon System, marking a significant expansion into the U.S. obesity care market.
Bayer has filed a lawsuit against Johnson & Johnson (NYSE:JNJ) and its subsidiary Janssen Biotech, alleging the healthcare giant is using "scientifically flawed" and misleading marketing to steal market share for its prostate cancer treatment, Erleada.
Bristol Myers Squibb (NYSE:BMY) announced Monday that its Phase 2 registrational study of Reblozyl (luspatercept-aamt) achieved its primary and key secondary endpoints, potentially expanding the drug’s use to patients with alpha-thalassemia.
Organon (NYSE:OGN) has entered into an exclusive global licensing agreement with Sebela Pharmaceuticals for Miudella, a hormone-free copper intrauterine device (IUD), as the healthcare company moves to bolster its reproductive health portfolio.
Gossamer Bio (NASDAQ:GOSS) announced topline results from its pivotal PROSERA Phase 3 Study on Monday, February 23, 2026.
Enhabit (NYSE:EHAB), a national provider of home health and hospice services, announced Monday that it has entered into a definitive agreement to be acquired by Kinderhook Industries.
Axsome Therapeutics (NASDAQ:AXSM) reported a surge in full-year 2025 revenue on Monday, fueled by the rapid commercial scaling of its depression and sleep disorder treatments.
ImmunityBio (NASDAQ:IBRX), the California-based immunotherapy leader, reported explosive 2025 financial results on Monday, signaling its successful transition into a high-growth commercial powerhouse.
